Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism

Journal of Hypertension

Volumn 26, Issue 12, 2008, Pages 2399-2405

  Bernini, Giampaolo ^a,b   Galetta, Fabio ^a   Franzoni, Ferdinando ^a   Bardini, Michele ^a   Taurino, Chiara ^a   Bernardini, Melania ^a   Ghiadoni, Lorenzo ^a   Bernini, Matteo ^a   Santoro, Gino ^a   Salvetti, Antonio ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Arterial stiffness; Backscatter analysis; Carotid arteries; Intima media thickness; Primary aldosteronism; Pulse wave velocity

Indexed keywords

ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTICLE; AUGMENTATION INDEX; BLOOD VESSEL WALL; CAROTID ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; FEMORAL ARTERY; HUMAN; MALE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PULSE WAVE; RADIAL ARTERY; TONOMETRY; VASCULAR FIBROSIS; AORTA; BLOOD FLOW; CASE CONTROL STUDY; ELASTICITY; FIBROSIS; HYPERALDOSTERONISM; HYPERTENSION; INTIMA; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PULSATILE FLOW; TUNICA MEDIA;

AORTA; CAROTID ARTERIES; CASE-CONTROL STUDIES; ELASTICITY; FEMALE; FEMORAL ARTERY; FIBROSIS; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; PULSATILE FLOW; RADIAL ARTERY; REGIONAL BLOOD FLOW; TUNICA INTIMA; TUNICA MEDIA;

EID: 59849099633     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831286fd     Document Type: Article

References (39)

1. Mano A, Tatsumi T, Shiraishi J, Keira N, Nomura T, Takeda M, et al. Aldosterone directly induces myocyte apoptosis through calcineurin- dependent pathways. Circulation 2004; 110:317-323.
2. Lijnen P, Petrov V. Induction of cardiac ?brosis by aldosterone. J Mol Cell Cardiol 2000; 32:865-879.
3. Burla AK, Neves MF, Oigman W, Mandarim-de-Lacerda CA. Eplerenone offsets cardiac and aortic adverse remodeling in spontaneously hypertensive rats. Int J Cardiol 2007; 114:64-70.
4. Burniston JG, Saini A, Tan LB,Goldspink DF. Aldosterone inducesmyocyte apoptosis in the heart and skeletalmuscles of rats in vivo. JMol Cell Cardiol 2005; 39:395-399.
5. Ramires FJ, Salemi VM, Ianni BM, Fernandes F, Martins DG, Billate A, et al. Aldosterone antagonism in an in?ammatory state: evidence for myocardial protection. J Renin Angiotensin Aldosterone Syst 2006; 7:162-167.
6. Rickard AJ, Funder JW, Fuller PJ, Young MJ. The role of the glucocorticoid receptor inmineralocorticoid/salt-mediated cardiac ?brosis. Endocrinology 2006; 147:5901-5906.
7. Susic D, Varagic J, Ahn J, Matavelli L, Frohlich ED. Long-term mineralocorticoid receptor blockade reduces ?brosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol 2007; 292:H175-H179.
8. Fuller PJ, YoungMJ.Mechanisms of mineralocorticoid action. Hypertension 2005; 46:1227-1235.
9. Goodfriend TL. Aldosterone - a hormone of cardiovascular adaptation and maladaptation. J Clin Hypertens (Greenwich) 2006; 8:133-139.
10. Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 2005; 70:347- 351.
11. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 2001; 12:308-314.
12. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16:104-107.
13. Schmidt BM, Schmieder RE. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16:80-86.
14. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol 2001; 28:783-791.
15. Tan LB, Schlosshan D, Barker D. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int J Cardiol 2004; 96:321- 333.
16. De Ciuceis C, Porteri E, Rizzoni D, Rizzardi N, Paiardi S, Boari GE, et al. Structural alterations of subcutaneous small-resistance arteries may predict major cardiovascular events in patients with hypertension. Am J Hypertens 2007; 20:846-852.
17. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
18. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91:2638-2642.
19. Holaj R, Zelinka T, Wichterle D, Petrak O, Strauch B, Widimsky J Jr. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25:1451-1457.
20. Strauch B, Petrak O, Wichterle D, Zelinka T, Holaj R, Widimsky J Jr. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19:909-914.
21. Lee RT, Grodzinsky AJ, Frank EH, Kamm RD, Schoen FJ. Structure- dependent dynamic mechanical behavior of ?brous caps from human atherosclerotic plaques. Circulation 1991; 83:1764-1770.
22. Takiuchi S, Rakugi H, Honda K, Masuyama T, Hirata N, Ito H, et al. Quantitative ultrasonic tissue characterization can identify high-risk atherosclerotic alteration in human carotid arteries. Circulation 2000; 102:766-770.
23. BerniniG, Moretti A, Orlandini C, Berti P, Miccoli P, Bardini M, et al. Plasma and urine aldosterone to plasma renin activity ratio in the diagnosis of primary aldosteronism. J Hypertens 2008; 26:981-988.
24. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.
25. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterialwall: a direct measurementwith ultrasound imaging. Circulation 1986; 74:1399-1406.
26. Kawasaki M, Takatsu H, Noda T, Ito Y, Kunishima A, Arai M, et al. Noninvasive quantitative tissue characterization and two-dimensional color- coded map of human atherosclerotic lesions using ultrasound integrated backscatter: comparison between histology and integrated backscatter images. J Am Coll Cardiol 2001; 38:486-492.
27. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27:2588-2605.
28. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL, Kass DA. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997; 95:1827-1836.
29. Plantinga Y, Ghiadoni L, Magagna A, Giannarelli C, Franzoni F, Taddei S, Salvetti A. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 2007; 20:392-397.
30. Hall CS, Scott MJ, Lanza GM, Miller JG, Wickline SA. The extracellular matrix is an important source of ultrasound backscatter from myocardium. J Acoust Soc Am 2000; 107:612-619.
31. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36:312-318.
32. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, in?ammation, and ?brosis. Hypertension 2001; 38:581-587.
33. Tunon J, Ruiz-Ortega M, Egido J. Regulation of matrix proteins and impact on vascular structure. Curr Hypertens Rep 2000; 2:106-113.
34. Intengan HD, Deng LY, Li JS, Schiffrin EL. Mechanics and composition of human subcutaneous resistance arteries in essential hypertension. Hypertension 1999; 33:569-574.
35. Park JB, Intengan HD, Schiffrin EL. Reduction of resistance artery stiffness by treatment with the AT(1)-receptor antagonist losartan in essential hypertension. J Renin Angiotensin Aldosterone Syst 2000; 1:40-45.
36. Porteri E, Rizzoni D, Mulvany MJ, De Ciuceis C, Sleiman I, Boari GE, et al. Adrenergic mechanisms and remodeling of subcutaneous small resistance arteries in humans. J Hypertens 2003; 21:2345-2352.
37. Rizzoni D, Porteri E, Gue? D, Piccoli A, Castellano M, Pasini G, et al. Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension. Hypertension 2000; 35:931-935.
38. Thybo NK, Mulvany MJ, Jastrup B, Nielsen H, Aalkjaer C. Some pharmacological and elastic characteristics of isolated subcutaneous small arteries from patients with essential hypertension. J Hypertens 1996; 14:993-998.
39. Schiffrin EL. Vascular stiffening and arterial compliance. Implications for systolic blood pressure. Am J Hypertens 2004; 17:39S-48S.